Market Overview

UPDATE: Jefferies & Company Reiterates Hold Rating, Raises PT on Gilead Sciences

Related GILD
Checking In On The Healthcare Sector Ahead Of Q1 Earnings Season
Don't Bail On Biotech ETFs: 'There Are Several Reasons Why The Sector Took A Breather'
Bulletproof Investing Performance: Week 17 (Seeking Alpha)

In a report published Wednesday, Jefferies & Company reiterated its Hold rating on Gilead Sciences (NASDAQ: GILD), and raised its price target from $55.00 to $59.00.

Jefferies noted, “On its earnings call, GILD highlighted key interim Phase 3 data on 7977+5885 in 1Q13 (although GILD may not disclose it), as well as 12-week treatment data for 7977+ daclatasvir and ELECTRON data for 7977+5885 in GT1 naives (at AASLD in Nov), to determine the ideal 7977 regimen for GT1 HCV. We are positive on 7977 prospects and continue work on sizing the HCV market to better analyze valuation.”

Gilead Sciences closed on Tuesday at $64.91.

Latest Ratings for GILD

Mar 2018BarclaysMaintainsOverweightOverweight
Feb 2018BMO CapitalMaintainsOutperformMarket Perform
Feb 2018Leerink SwannMaintainsMarket PerformMarket Perform

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (GILD)

View Comments and Join the Discussion!